13 results about "Type A Monoamine Oxidase" patented technology

Pharmaceutical compositions for the transmucosal delivery of N-N-dimethyltryptamine (DMT) acceptable salt or prodrug thereof in combination with a monoamine oxidase inhibitor to achieve desired bioavailability suitable for the treatment of neurological disorders.

The present application provides a beta-coclinic alkaloid coumaroyl glucoside compound, an extraction method and application thereof, and a monoamine oxidase inhibitor. The beta-coclinic alkaloid coumaroyl glucoside compound provided by the present application has a structure shown in formula 1 or formula 2, is novel in structure, has good monoamine oxidase inhibitory activity, can slow down the consumption of monoamine neurotransmitters in the brain, slow down oxidative damage, realize the treatment of neurodegenerative diseases, and can be used for preparing a monoamine oxidase inhibitor or an anti-neurodegenerative disease drug, and has a wide application prospect.

Pharmaceutical compositions for the transmucosal delivery of N-N-dimethyltryptamine (DMT) acceptable salt or prodrug thereof in combination with a monoamine oxidase inhibitor to achieve desired bioavailability suitable for the treatment of neurological disorders.

The present disclosure describes methods and compositions for treating CDKL5 deficiency disorder (CDD), a severe neurodevelopmental disorder characterized by early-onset, treatment-resistant epilepsy and global developmental impairment. The invention describes the use of monoamine oxidase inhibitors (MAO-Is), particularly MAO-A inhibitors such as harmine, for reducing convulsive seizure frequency in patients suffering from CDD. The MAO-Is may be administered alone or in combination with one or more anti-epileptic drugs (AEDs). The disclosed methods further include treatment strategies targeting CDKL5 paralogues to modulate neuronal signaling pathways and synaptic function. In vivo and in vitro studies demonstrate the efficacy of MAO-Is in upregulating CDKL5 protein expression and restoring synaptic homeostasis, offering a novel therapeutic approach for treating CDKL5-related epilepsy and other symptoms associated with the disorder.

Disclosed are methods of treating a subject having a disease or disorder by administering a monoamine oxidase inhibitor in combination with a serotonin receptor agonist, which in some embodiments is a deuterated serotonin receptor agonist. In some aspects, the disclosure further relates to pharmaceutical compositions and kits comprising a monoamine oxidase inhibitor and a serotonin receptor agonist. In some embodiments, the monoamine oxidase inhibitor is a MAO-A-selective inhibitor such as CX157, and the serotonin receptor agonist is a serotonin 2A receptor agonist such as N,N-dimethyltryptamine (DMT), or deuterated DMT.

A first aspect of the invention relates to betahistine, or a pharmaceutically acceptable salt thereof, and a monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subject. A second aspect of the invention relates to a method of treating or preventing one or more symptoms of vertigo in a subject, said method comprising administering to a subject (i) betahistine, or a pharmaceutically acceptable salt thereof, and (ii) a monoamine oxidase inhibitor.

The invention provides dosage forms that contain both a monoamine oxidase inhibitor (MAOI) and a beta blocker (e.g., propranolol, metoprolol, carvedilol, timolol, carteolol, atenolol, nebivolol, sotalol, bucindolol, nadalol, celirpolol, nebivolol, betaxolol, esmolol, bisoprolol, oxprenolol, penbutolol, labetalol, acebutolol, and pindolol) and methods of making and using same in, for example, for the treatment of psychiatric disorders (e.g., depression, major depressive disorder, major depressive disorder with anxious distress, treatment resistant depression, anxious depression, and mixed anxiety and depression). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

The invention provides compositions and methods for the treatment of depression and other psychiatric disorders. In particular, the invention provides sustained- or controlled-release formulations, particularly extended or slow release formulations, which include at least one monoamine oxidase inhibitor (MAOI), as well as combination therapies that include at least one MAOI and at least one norepinephrine-reuptake-inhibitor (NRI), for use in such compositions and methods. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

The invention discloses a monoamine oxidase inhibitor type near-infrared fluorescent probe, a synthesis method thereof and application of the monoamine oxidase inhibitor type near-infrared fluorescent probe in photothermal therapy of tumors. The method comprises the following steps: (1) synthesizing the monoamine oxidase inhibitor type near-infrared fluorescent probe SINH; and (2) applying the SINH probe to monoamine oxidase activity inhibition, organelle co-localization imaging and targeted phototherapy tumor treatment. The problem that a traditional inhibitor type probe only targets tumors and does not combine with illumination for phototherapy is solved; the inhibitor type near-infrared fluorescent probe has near-red absorption and emission properties, so that interference of background fluorescence signals can be weakened, and the tissue penetration depth can be increased; the probe disclosed by the invention not only has strong inhibition on the growth of SH-SY5Y cells with high MAO expression, but also can be used for carrying out photodynamic and photothermal therapy on subcutaneous tumor-bearing mice with high MAO expression, and has a very good inhibition effect on the growth of tumors with high MAO expression.

The disclosure is directed to methods of generating induced pluripotent Procavia capensis stem cells that combine transfection and chemical reprogramming. Specifically, the disclosure provides methods of generating induced pluripotent P. capensis stem cells that include generating primed P. capensis cells by chemically reprogramming primary P. capensis cells transfected with OCTA. 80X2. KI.F4. CMYC. and GLIS1 by culturing the cells, generating pre-induced P. capensis cells from the primed P. capensis cells by transfecting the primed P. capensis cells with OCT4. 80X2. KLF4, CMYC, and NANOG and culturing these cells, and generating the induced pluripotent P. capensis stem cells from the pre-induced P. capensis cells by transfecting the pre-induced P. capensis cells with OCT4, SOX2, KLF4. CMYC, NANOG, IJN28A. and SV40 and culturing the transfected cells. In other embodiments, the primary P. capensis cells are cultured to generate pre-induced P. capensis cells, which are then transfected with at least OCT4ISOX2IKLF4ICMYC. and SV40 T-antigen or an shRNA targeting TP53 and cultured again. The culturing uses a culture medium supplemented with an HD AC inhibitor, a GSK-3 inhibitor, a monoamine oxidase inhibitor, an activator of eukaryotic adenylyl cyclase, a retinoid, a DOT1L inhibitor, and a TGF-β inhibitor. The disclosure is also directed to cell culture media useful in such methods and induced pluripotent P. capensis stem cells expressing at least OCT4, 80X2, KLF4, CMYC, NANOG, LIN28A, and SV40.

The present disclosure relates to methods of transitioning patients or obese patients being treated with vortioxetine to treatment with a monoamine oxidase inhibitor (MAOI). The methods provided include delaying administration of the MAOI for certain time periods after stopping administration of vortioxetine. The patients or obese patients possess various capabilities of metabolizing vortioxetine. The current disclosure also includes methods of switching patients to a MAOI intended to treat psychiatric disorders while being treated with vortioxetine. The methods disclosed further comprise determining vortioxetine plasma clearance and washout time for patients with different body fat status and / or different CYP2D6 metabolizer status.

The invention relates to formulations of tryptamines and monoamine oxidase inhibitors and uses thereof in methods of treatment. In particular, compositions having a modified-release of a tryptamine and an immediate release of a monoamine oxidase inhibitor. Also disclosed are methods of treating disorders with tryptamines in combination with monoamine oxidase inhibitors.

The present invention provides compositions comprising a monoamine oxidase inhibitor (MAOI) and a beta receptor blocker (e.g., a beta receptor inhibitor). The invention relates to a dosage form of two of propranolol, metoprolol, carvedilol, timolol, carteolol, atenolol, nebivolol, sotalol, bunenolol, naldalol, seribolol, nebivolol, betalol, esmolol, bisoprolol, oxyprenolol, pentobutolol, labeolol, acebutolol and indolol. And methods of making the dosage forms and using the dosage forms for, for example, the treatment of psychiatric disorders (e.g., depression, major depressive disorder, major depressive disorder associated with anxiety pain, refractory depression, anxiety depression, and mixed anxiety and depression). This abstract is intended as a scanning tool for search purposes in the particular art and is not intended as a limitation on the present invention.